The benefits of bendamustine are increasingly being recognised in the relapsed setting but its optimal use has yet to be defined. Based on a review of current data, the UK Myeloma Forum has produced a position statement providing recommendations for the use of bendamustine as a treatment for myeloma patients in the UK.